SDX-7320 plus eribulin for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative metastatic breast cancer (estrogen/progesterone receptors ≤10% and HER2-negative).
- Your cancer is advanced/regionally recurrent or metastatic, and you have had up to 2 prior treatment lines for the advanced/metastatic setting.
- You have received anthracycline and taxane chemo before (or your doctor says you were not able to take them) and you can start eribulin.
- You must have metabolic dysfunction, such as HbA1c above 5.5 and/or a BMI of 30 or higher.
- Your body has to be strong enough for treatment (ECOG performance status of 0–1 and blood/liver/kidney numbers within limits).
- You must have measurable cancer or a mainly “lytic” bone lesion, and you’re willing to fast before treatment days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve outcomes in people with advanced triple-negative breast cancer who have already tried at least two other chemotherapies.
This trial tests a new combination treatment for a specific type of advanced triple-negative breast cancer. It compares the study drug given alone versus with another medicine, to see which is more effective in slowing the cancer down.
This trial tests a chemotherapy drug called eribulin, alone or with other medicines, in people with advanced HER2-negative breast cancer that has already been treated with an antibody-drug conjugate (ADC). It aims to see if eribulin can help when standard ADC treatment has stopped working.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
This trial tests whether combining the immunotherapy drug cadonilimab with the chemotherapy eribulin works better than eribulin alone for people with recurrent or metastatic triple-negative breast cancer. It aims to see if the combination can shrink tumors or slow the disease.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.